Clinical Trials Browser

Cholangiocarcinoma × Neoadjuvant Therapy × Gastrointestinal × Clear all

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06369480 2024-04-17

Prognostic Factors for Survival in Patients With Cholangiocarcinoma

Gastrointestinal

Cholangiocarcinoma

NCT02773485 2022-10-21

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

Phase 3 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT04523402 2020-08-21

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT04506281 2020-08-10

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma